stimulants of the reticuloendothelial system, such as BCG or Corynebacterium parvum, functions by increasing the availability of macrophages. Cytotoxic lymphocytes: Tumours at subcutaneous sites are vulnerable to attack by cytotoxic lymphoid cells; the most effective of these are immunoblasts; they have the capacity to traverse capillary beds and thus reach extravascular sites and they have been shown to be directly cytotoxic. Immunoblasts are released into the efferent lymph of a stimulated node between 3 and 10 days after antigenic stimulation. However, growing tumours interfere with the release of such cells from draining nodes; possibly the continual bombardment of nodes by antigens causes a local situation such that the immunoblasts no longer leave the node. This 'paralysis' of the node does not interfere with the production of antibodies but prevents subcutaneous tumours from being assailed by imnumoblasts. This phenomenon may also explain why in an animal bearing an antigenic subcutaneous tumour this may grow apparently unopposed, while other sites such as the peritoneal cavity or the vascular space are resistant to tumour challenge.
The value of irradiated tumour autografts: The lymph node 'paralysis' can be by-passed by immunizing distant nodes with tumour cells that have been rendered non-viable by prior exposure to X-rays. Nodes stimulated in this way function normally and discharge immunoblasts. This provides a possible rationale for the therapeutic effects that have been observed following autografting with irradiated tumours in some animal systems. It must be stressed, however, that this procedure has only been effective when the amount of viable tumour which needed to be eradicated was small. Treatment with immunoblasts: Another way of overcoming the lymph node 'paralysis' is to inject immunoblasts derived by immunizing 'donor' animals with a piece of the tumour to be treated. Following such immunization the immunoblasts are collected from the lymph of such animals and injected into the tumour-bearing animal. This procedure, again, has been found to produce an arrest of tumour growth in certain carefully selected animal systems. The large number of immunoblasts needed to produce a beneficial effect would appear to make this procedure impractical for clinical trial at the present time.
Conclusion
In conclusion, it must be emphasized that immunological procedures can be shown to be of therapeutic benefit in carefully manipulated animal situations but as yet we have no indication that any such procedures would be useful in tumour problems encountered in man. One thing which appears to be clear is that the immuno-logical procedures known to us at present can only achieve the eradication of relatively few cells and that as far as we can see immunotherapy can at best only assist established methods of treatment after these have achieved removal of the vast bulk of the tumour.
Dr K D Bagshawe (EdgarLaboratory, Fulham Hospital, London W6)
Choriocarcinoma
During the past decade interest has focused on the proposition that tumours may have antigens which are, to some extent, foreign to their host and that these antigens may provide a target for therapeutic attack. The failure attending this approach, so far, has been attributed to a variety of mechanisms and notably to the weakness of tumour-associated antigens. In the case of choriocarcinoma it was evident that strong antigenic differences might be involved and if so, should not immunotherapy be successful here?
Placental choriocarcinoma is an allograft which arises from the trophoblast of one individual and invades another. The host often has a humoral response to antigens which the tumour inherits from the male parent and there is often a good mononuclear cell reaction to the tumour. Yet the fact of the occurrence of the tumour indicates the inadequacy of the host-versustumour reaction alone to control it. A marked cellular reaction does, however, favour the response to chemotherapy (Elston 1969) and where chemotherapy has failed to eliminate the tumour me have tried to augment the immunological contribution.
The methods used included repeated active nonspecific immunization with BCG, repeated active specific immunization with tissues from the patient's husband and passive immunization with heterologous antisera raised to the husband's leukocyte antigens. Immunotherapy has been initiated when there was only minimal residual disease. No convincing success can be claimed for these immunotherapeutic procedures (Bagshawe & Golding 1970) .
Failure to get encouraging results with choriocarcinoma clearly requires us to look more closely into our assumptions about the host-tumour relationship. Current theory leads us to expect that the most strongly antigenic tumours should be eliminated and it also leads us to expect that antigens expressed by the host, but not expressed by the tumour, would not influence host-tumour interaction. This has been studied in choriocarcinoma and in patients with other forms of trophoblastic neoplasia with respect to the HL-A, ABO and Rh systems.
Studies in collaboration with Dr Sylvia D Lawler (Bagshawe et al. 1971 ) on this series have shown that choriocarcinomas usually differ from their respective hosts at one or both of the HL-A sub-loci where such differences are possible. Antibodies to HL-A factors have been present both in patients who have gone into complete remission and in those who did not respond fully to chemotherapy.
The number of ABO incompatible conceptions associated with choriocarcinoma is probably fewer than expected but ABO incompatibility is not an absolute barrier to choriocarcinoma. Group AB women are prone to a most aggressive form of choriocarcinoma which is often resistant to chemotherapy. A group 'A' woman is about ten times as likely to get choriocarcinoma if her husband is group 0 than if he is group A. A woman who has a mole has the best chance of no malignant sequelke if her husband is the same group as herself.
The data as a whole appear to present two distinct but superimposed pictures. One is consistent with the theory that the most antigenic tumours tend to regress either spontaneously or with the aid of chemotherapy and that the least antigenic tumours do not. The other picture is that the more antigenic the host towards the tumour, the more aggressive is the tumour and the more resistant it proves to chemotherapeutic attack.
If the choriocarcinoma-host situation is representative of the tumour-host situation in general then it is clear that the phenomenon of antigen loss, much studied in the 1950s, may assume a new significance. It would also suggest that our immunotherapeutic approach to cancer has taken account of only one side of a two-sided problem and that it may, therefore, need to be rethought.
Dr G Hamilton Fairley (St Bartholomew's Hospital, London EC1)
Evidence for Antigenicity in Human Tumours with Reference both to Melanoma and Acute Leukiemia As we have heard already in this symposium, tumour-associated antigens exist in experimental animal tumours, and immunological reactions against these antigens can influence the course of the malignant disease. However, because of the difficulties of research in man, the situation is not as clear as in animals. The main reason for this is that most of the early experiments proving the existence of these antigens involved the transplantation of living malignant cells into genetically identical animals. In man such experiments are unethical and syngeneic recipients, with the exception of identical twins, do not exist. Nevertheless, recent work using autoimmunization with irradiated malignant cells, mixed lymphocyte reactions, in vitro studies showing cytotoxicity of serum and lymphoid cells against tumour cells, and immunofluorescent techniques have demonstrated that tumour-associated antigens are present in human malignant tissue. There has been extensive work in two diseases, malignant melanoma and acute leukxemia, the details of which were published recently (Hamilton Fairley 1970) .
In malignant melanoma antibody directed against the cell membrane of the tumour cells is usually present in patients with localized disease, and usually absent in those with widespread metastases. However, immunization of the patient's own irradiated melanoma cells may lead to the temporary presence of antibodies in the blood even in patients with advanced disease, and cytotoxic lymphocytes may also develop following immunization.
Similarly in acute leukxemia the ability of the patient's lymphocytes to recognize their own leukaemic cells as 'foreign' may be increased by autoimmunization with irradiated leukemic cells.
If such immunization procedures could lead to effective immunological reaction, it might be possible in the future to exploit these in the treatment of patients. However, with the exception of the results obtained by Mathe (1970) and Mathe et al. (1969) in maintaining remissions in acute lymphoblastic leukxmia, it is premature to speak of immunotherapy in man at the present time. The most which can be expected is that by mounting a powerful immune response against the tumour antigens a small number of malignant cells will be killed. The place for immunotherapy is after the classical methods of reducing the number of tumour cells to the absolute minimum, i.e. surgerv, radiotherapy, or intensive chemotherapy.
